PSA Screening Recommendations
For average-risk men, begin discussing PSA screening at age 50 and offer shared decision-making for screening between ages 55-69 years, while avoiding routine screening in men aged 70 and older or those with life expectancy less than 10-15 years. 1, 2
Age-Based Screening Framework
Average-Risk Men (Ages 50-69)
The most recent USPSTF 2018 guideline recommends shared decision-making for men aged 55-69 years, emphasizing that the decision must be individualized after discussing potential benefits and harms 2. The evidence shows screening may prevent approximately 1.3 prostate cancer deaths per 1,000 men screened over 13 years, but comes with significant harms including overdiagnosis (37 additional men diagnosed for every 1 death prevented), false positives, and treatment complications 2, 3.
- Key point: The net benefit is small and depends heavily on patient values regarding the trade-off between modest mortality reduction versus risks of incontinence (20% after surgery), erectile dysfunction (67% after surgery), and overtreatment 2
High-Risk Populations: Earlier Screening
Begin screening discussions at age 45 for:
- African-American men
- Men with first-degree relative diagnosed with prostate cancer before age 65
Begin at age 40 for:
- Men with multiple first-degree relatives with early prostate cancer (before age 65) 1
This earlier approach for high-risk groups is supported by the American Cancer Society 2016 guidelines and European Association of Urology 2018 guidelines 1. African-American men have increased prostate cancer risk and are paradoxically less likely to be screened despite their elevated risk 2.
Men Aged 70 and Older
Do not screen men aged 70 or older - the USPSTF gives this a Grade D recommendation (recommend against) 1, 2. The harms clearly outweigh benefits in this age group due to increased false-positives, biopsy complications, and treatment harms, while competing mortality from other causes becomes dominant 4, 2.
Men Under Age 40
Avoid routine screening in men under age 40 unless they have very high familial risk 1. Research shows essentially no prostate cancer detected in men under 45 regardless of PSA level, with over 99% having PSA <4 ng/mL 5. Current practice shows 7% of men aged 18-39 receive PSA testing, representing low-value care that should be eliminated 6.
Life Expectancy Considerations
Do not screen men with life expectancy less than 10-15 years, regardless of age 1. Prostate cancer typically has an indolent course - in men with well-differentiated tumors, only 6 deaths per 1,000 person-years occur from prostate cancer versus 75% dying from other causes 4.
Screening Intervals
If screening is pursued after shared decision-making:
- Men with PSA <3.0 ng/mL: Rescreen every 3+ years
- Men with PSA 3.0-3.9 ng/mL: Rescreen at 2 years
- Men with PSA ≥4.0 ng/mL: Consider biopsy 7
Critical Caveats
The controversy remains unresolved: The European ERSPC trial showed 21% relative reduction in prostate cancer mortality, while the US PLCO trial showed no benefit 2, 3. This divergence reflects differences in screening intensity and contamination in control groups.
Overdiagnosis is substantial: For every prostate cancer death prevented, 37 additional men receive diagnoses through screening, many of whom would never have experienced symptoms 2, 3. This represents the core tension in PSA screening.
Never screen without prior counseling about the uncertain benefits, definite harms of false-positives, biopsy complications, and treatment side effects including permanent incontinence and erectile dysfunction 1, 2.
Do not screen men who do not express a clear preference for screening after being informed of the evidence 2.